C4 Therapeutics, Inc. Capital Expenditures Incurred but Not yet Paid
C4 Therapeutics, Inc. (CCCC) reported Capital Expenditures Incurred but Not yet Paid of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-11
- C4 Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-06-30 was -$38.00K, a 112.93% decline year-over-year.
- C4 Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-03-31 was $38.00K.
- C4 Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was -$269.00K.
- C4 Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-06-30 was $294.00K, a 2161.54% increase year-over-year.
- C4 Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- C4 Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $18.00K, a 96.19% decline from fiscal 2022.
- C4 Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2022 was $473.00K.
- C4 Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2021 was $0.00.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$38.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | ||
| 2026-03-31 | $38.00K 10-Q · filed 2026-05-12 | |||
| 2025-09-30 | -$269.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $25.00K derived: sum of 2 quarters · filed 2026-08-11 | $25.00K 10-Q · filed 2025-11-06 | $25.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $294.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $294.00K 10-Q · filed 2026-08-11 | $294.00K derived: sum of 3 quarters · filed 2026-08-11 | $281.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-12 | $0.00 derived: sum of 2 quarters · filed 2026-05-12 | -$13.00K derived: sum of 3 quarters · filed 2026-05-12 | $0.00 derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$13.00K derived: sum of 2 quarters · filed 2025-11-06 | $0.00 derived: sum of 3 quarters · filed 2025-11-06 | $0.00 10-K · filed 2025-02-27 |
| 2024-09-30 | -$13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | -$36.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $13.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $13.00K 10-Q · filed 2025-08-07 | -$23.00K derived: sum of 3 quarters · filed 2025-08-07 | -$192.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-08 | -$36.00K derived: sum of 2 quarters · filed 2025-02-27 | -$205.00K derived: sum of 3 quarters · filed 2025-02-27 | -$178.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-12-31 | -$36.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$205.00K derived: sum of 2 quarters · filed 2025-02-27 | -$178.00K derived: sum of 3 quarters · filed 2025-02-27 | $18.00K 10-K · filed 2025-02-27 |
| 2023-09-30 | -$169.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | -$142.00K derived: sum of 2 quarters · filed 2024-08-01 | $54.00K 10-Q · filed 2023-11-01 | -$928.00K derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-06-30 | $27.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $223.00K 10-Q · filed 2024-08-01 | -$759.00K derived: sum of 3 quarters · filed 2024-08-01 | -$2.57M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $196.00K 10-Q · filed 2024-05-08 | -$786.00K derived: sum of 2 quarters · filed 2024-05-08 | -$2.60M derived: sum of 3 quarters · filed 2024-05-08 | $617.00K derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$982.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$2.80M derived: sum of 2 quarters · filed 2024-02-22 | $421.00K derived: sum of 3 quarters · filed 2024-02-22 | $473.00K 10-K · filed 2024-02-22 |
| 2022-09-30 | -$1.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $1.40M derived: sum of 2 quarters · filed 2023-11-01 | $1.46M 10-Q · filed 2023-11-01 | $1.46M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | $3.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $3.27M 10-Q · filed 2023-08-08 | $3.27M derived: sum of 3 quarters · filed 2023-08-08 | $3.27M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $52.00K 10-Q · filed 2023-05-04 | $52.00K derived: sum of 2 quarters · filed 2023-05-04 | $52.00K derived: sum of 3 quarters · filed 2023-05-04 | -$670.00K derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $0.00 derived: sum of 2 quarters · filed 2023-02-23 | -$722.00K derived: sum of 3 quarters · filed 2023-02-23 | $0.00 10-K · filed 2023-02-23 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$722.00K derived: sum of 2 quarters · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | |
| 2021-06-30 | -$722.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $722.00K 10-Q · filed 2022-05-05 | |||
| 2020-09-30 | -$4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$2.00K derived: sum of 2 quarters · filed 2021-11-10 | $10.00K 10-Q · filed 2021-11-10 | $84.00K derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $14.00K 10-Q · filed 2021-08-11 | $88.00K derived: sum of 3 quarters · filed 2022-02-24 | |
| 2020-03-31 | $12.00K 10-Q · filed 2021-05-13 | $86.00K derived: sum of 2 quarters · filed 2022-02-24 | ||
| 2019-12-31 | $74.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $172.00K 10-K · filed 2022-02-24 | ||
| 2019-09-30 | $98.00K 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |